Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBS301
- Development stage
- Phase 1
- Lead developer
- Mabworks Biotech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MBS301 is a glyco-engineered, fully afucosylated bispecific monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2). It is constructed by combining two half antibodies derived from trastuzumab and pertuzumab, enabling simultaneous binding to two distinct epitopes on HER2. This biparatopic design enhances antitumor activity through improved antibody-dependent cell cytotoxicity (ADCC) and T lymphocyte stimulation. The afucosylation increases its affinity for FcγRIIIa receptors on immune effector cells, further boosting ADCC against HER2-positive cancer cells. Developed by Beijing Mabworks Biotech, MBS301 is being investigated primarily for the treatment of HER2-positive solid tumors that are resistant to trastuzumab[1][3][4][5].
- Other names
- Recombinant humanized anti-HER-2 bispecific monoclonal antibody MBS301Anti-ERBB2-afucosylated bispecific antibodyAnti-ERBB-2-afucosylated bispecific antibodyAnti-ERBB 2-afucosylated bispecific antibodyRecombinant humanised bispecific monoclonal antibody
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on MBS301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBS301.